MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

    M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)

    Objective: We aim to describe the molecular pathways at the crossroad of etiology and susceptibility in PD, focusing on Rin, coded by the recently associated…
  • 2017 International Congress

    The effects of dual task on the finger tapping performance of Parkinson’s disease.

    A. Miyake, T. Yamamoto, H. Kawasaki, T. Furuya, T. Fukuoka, K. Takahashi, N. Tamura, N. Araki (irumagun moroyama town, Japan)

    Objective: In the present study, we aim to analyze the effects of a dual task on repetitive finger tapping (FT) performance in patients with Parkinson’s…
  • 2017 International Congress

    Impacts of CSF kynurenine pathway on neuroinflammaion in patients with Parkinson’s disease

    K. Iwaoka, T. Maeda, Y. Terayama (Morioka, Japan)

    Objective: To investigate the interaction between the KYN pathway and the neuroinflammation in PD. Background: In Parkinson's disease (PD), some pathologic mechanisms are reported such as mitochondrial dysfunction, inflammatory reaction and oxidative stress. Inflammatory cytokines are noticed as one of an important mediator of inflammatory reaction in the central nervous system (CNS). Kynurenine (KYN) pathway is also known to play an important role for degradation of oxidative stress in the CNS. Disproportion of KYN pathway can act neurotoxically and induce several neurological diseases including PD. In metabolites produced from this pathway, 3-hydroxykynurenine (3-HK) and quinolinic acid are as neurotoxic and kynurenic acid (KYNA) is neuroprotective. Methods: We could recruited 20 patients with PD (age; 57-80 y, median; 69.5 y) and 13 controls (age; 23-83 y, median; 75.0 y). Clinical severity was evaluated with Hoehn and Yahr staging.Samples of the cerebrospinal fluid (CSF) were obtained between 9:00 and 10:00AM after overnight bed-rest and before breakfast in PD patients. Control CSF were corrected from normal pregnant women on their lumbar anesthesia ante partum who had no neurologically abnormal condition confirmed by neurological examination and neuroimagings in advance. All CSF samples were promptly cryopreserved in a deep freezer (-80 ℃).CSF levels of KYN or 3-HK were measured using with the high-performance liquid chromatography coupled with the electrochemical detector. CSF levels of IL-6, IL-1β, TNF-α and IFN-γ were also measures using with an ELISA. Statistical analysis was performed and the significance level was set at p<0.05.This study was carried out after approval in our university ethical review board and written informed consents from all participants. Results: CSF levels of KYN in PD and control were 22.6 to 90.3 nM (median; 49.0 nM) and 9.5 to 51.4 nM (30.5 nM), respectively. CFS levels of 3-HK were 0.2 to 13.3 nM (4.25 nM) and 0.001 to 3.96 nM (1.55 nM), respectively. These were significantly higher in PD than in control (p<0.05). These were still statistically significant after normalization to CSF levels of triptophan(p<0.05).There was a positive correlation between the CSF levels of 3-HK and TNF-α (r=0.54,p=0.055). Conclusions: We could suggest that elevated CSF levels of KYN and 3-HK and positive correlation between 3-HK and TNF-α in patients with PD is associated with neuroinflammation in the CNS. 
  • 2017 International Congress

    Listen to your heart: ordinal pattern statistics reveal altered cardiac rhythm dynamics in LRRK2-nonmanifesting carriers

    C. Carricarte Naranjo, C. Marras, N. Visanji, A. Lang, L. Sanchez-Rodriguez, A. Machado García (La Habana, Cuba)

    Objective: To assess the complexity of heart rate variability (HRV) dynamics in LRRK2-nonmanifesting carriers compared to healthy individuals. Background: Cardiovascular autonomic dysfunction is an early…
  • 2017 International Congress

    Admixing augments nigral dopaminergic correlates during development to impart resistance to MPTP-toxicity at adulthood

    V. D J, Y. H, R. T R, P. Anand Alladi (Bangalore, India)

    Objective: Establish the developmental basis for varying nigral dopaminergic (DA) correlates in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) susceptible C57BL/6, MPTP resistant CD-1 and their resistant crossbred mice. Background:…
  • 2017 International Congress

    Efficient control of dopamine neuron physiology for rescuing disease phenotypes

    T. Rumbell, J. Kozloski (Yorktown Heights, NY, USA)

    Objective: Dopamine neurons (DAs) of the substantia nigra degenerate in Parkinson's disease and are disrupted in Huntington's disease. Here we propose single cell computational modeling…
  • 2017 International Congress

    Effectiveness of lead position with MER to determine STNs: A study of MER with DBS for quantifying the effects of DBS in Parkinson`s disease

    V. Rama Raju, R. Borgohain (HYDERABAD, India)

    Objective: To quantify the effectiveness of MER with DBS, characterize Parkinson`s disease symptoms/extract MER signal features of STN Background: Parkinson`s disease targeting CNS, causing group of neurons…
  • 2017 International Congress

    Treatable Rare Movement Disorders

    E. Gatto, H. Jinnah, A. Espay, J. Jankovic, K. Bhatia, M. Rodriguez, V. Fung, F. Cardoso, M. Rodriguez Oroz, A. Albanese, A. Muenchau, A. Chade, M. de Koning-Tijssen, M. Stamelou, P. Garcia Ruiz, C. Uribe Roca, F. Morgante, A. Dela Cerda, L. Schoels, J. Miyasaki, J. Ferreira (Buenos Aires, Argentina)

    Objective: To classify therapies of RMD into enzyme replacement therapy, specific dietary changes, avoidance or management of certain triggers, and  others Background: Rare diseases (RD)…
  • 2017 International Congress

    Prevalence of Restless Legs Syndrome in hemodialyzed patients

    I. Estrada-Bellmann, S. Castillo-Torres, C. Cerda-Contreras, J. Peña-Avendaño, D. Ortiz-Zacarías (Monterrey, Mexico)

    Objective: To determine the prevalence of restless legs syndrome in patients on hemodialysis. Background: The restless leg syndrome (RLS) is a frequent complication of hemodialysis…
  • 2017 International Congress

    Using measurements from wearable sensors for automatic scoring of Parkinson’s disease motor states

    I. Thomas, F. Bergquist, R. Constantinescu, D. Nyholm, M. Senek, M. Memedi (Falun, Sweden)

    Objective: The aim of this study was to investigate the concurrent validity of an objective gait measure for assessment of motor states in advanced Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley